Evidence map›Paper›PMID 37253049›Full record

ArticlePloS one2023

A cross-circulatory platform for monitoring innate allo-responses in lung grafts.

Matthieu Glorion, Florentina Pascale, Jérôme Estephan, Maxime Huriet, Carla Gouin, Céline Urien, Fany Blanc, Julie Rivière, Christophe Richard, Valérie Gelin and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Machine Perfusion and Bioengineering Strategies in Transplantation-Beyond the Emerging Concepts.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Matthieu GlorionDepartment of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France.
Florentina PascaleDepartment of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France.
Jérôme EstephanUniversité Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.
Maxime HurietUniversité Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.
Carla GouinUniversité Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.
Céline UrienUniversité Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.
Fany BlancUniversité Paris-Saclay, INRAE, AgroParisTech, GABI, Jouy-en-Josas, France.
Julie RivièreUniversité Paris-Saclay, INRAE, AgroParisTech, GABI, Jouy-en-Josas, France.
Christophe RichardUniversité Paris-Saclay, INRAE, UVSQ, BREED, Jouy-en-Josas, France.
Valérie GelinUniversité Paris-Saclay, INRAE, UVSQ, BREED, Jouy-en-Josas, France.
Julien De WolfDepartment of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France.
Morgan Le GuenDepartment of Anesthesiology, Foch Hospital, Suresnes, France.
Antoine MagnanDepartment of Pulmonology, Foch Hospital, Suresnes, France.
Antoine RouxDepartment of Pulmonology, Foch Hospital, Suresnes, France.
Isabelle Schwartz-CornilUniversité Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.ORCID 0000-0002-3485-1765
Edouard SageDepartment of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France.
Université de Versailles Saint-Quentin-en-Yvelines · FRHôpital Foch · FRAgroParisTech · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung transplantation is the only curative option for end-stage chronic respiratory diseases. However the survival rate is only about 50% at 5 years. Although experimental evidences have shown that innate allo-responses impact on the clinical outcome, the knowledge of the involved mechanisms involved is limited. We established a cross-circulatory platform to monitor the early recruitment and activation of immune cells in an extracorporeal donor lung by coupling blood perfusion to cell mapping with a fluorescent marker in the pig, a commonly-used species for lung transplantation. The perfusing pig cells were easily detectable in lung cell suspensions, in broncho-alveolar lavages and in different areas of lung sections, indicating infiltration of the organ. Myeloid cells (granulocytes and monocytic cells) were the dominant recruited subsets. Between 6 and 10 h of perfusion, recruited monocytic cells presented a strong upregulation of MHC class II and CD80/86 expression, whereas alveolar macrophages and donor monocytic cells showed no significant modulation of expression. This cross-circulation model allowed us to monitor the initial encounter between perfusing cells and the lung graft, in an easy, rapid, and controllable manner, to generate robust information on innate response and test targeted therapies for improvement of lung transplantation outcome.

Indexed as

Lung TransplantationAnimalsGenes, MHC Class IILungPerfusionSwine

Identifiers

PMID37253049
PMCPMC10228766
OpenAlexW4378782129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.